Poster Presentation

Trastuzumab-ADC engineered as ICAM-1 refractory has enhanced activity in HER2+ cancers

 

Publication

Enhanced therapeutic antibodies and antibody-drug conjugates refractory to immunosuppressive ICAM-1

 

Publication

NAV-001, antibody-drug conjugate targeting mesothelin and counteracting CA125 inhibitory effects

 

Publication

NAV-003, Bispecific Targeting Mesothelin With Improved Cytotoxicity Against Humoral Immunosuppressed Tumors

 

Publication

NAV-006, next-gen rituximab with enhanced effector function by counteracting CA125 immunosuppression

 

Poster Presentation

The ADC NAV-001 targets mesothelin, deploys a novel payload, and is refractory to CA125 inhibition